ACLARION, INC. Proceeds from Short-term Debt
ACLARION, INC. (ACON) reported Proceeds from Short-term Debt of $0 for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2022-11-14
- 2022-09-30: Proceeds from Short-term Debt 9 month $0.00.
- 2021-09-30: Proceeds from Short-term Debt 9 month $125.00K.
| Period end | Proceeds from Short-term Debt 9 month |
|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 |
| 2021-09-30 | $125.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |